Market Research Blog

[285 Pages Report] Immunostimulants are drugs that stimulate the immune system by accelerating the activity of immune cells, tissues, and organs and also help the body to fight against sepsis and diseases.

As per Future Market Insights’ latest industry analysis, the global immunostimulants market was valued at around US$ 102.2 Bn in 2021 and is anticipated to exhibit a CAGR of close to 6.2% over the forecast period (2022-2032). Against this backdrop, the market size is projected to reach US$ 108.2 Bn in 2022.

Growing prevalence of autoimmune diseases is fueling the development of immunostimulants. Around 4% of the world’s population is affected by different autoimmune diseases, which also include multiple sclerosis and rheumatoid arthritis. In the U.S., autoimmune diseases represent the third most common chronic disorder.

Market Outlook:

Get a Sample Copy of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15145

Further, demand for immunostimulants in countries such as India and China is expected to increase at a considerable pace. Developing economies are refining their healthcare framework, owing to increasing accessibility to resources, and increasing efforts by manufacturers to gain drug approvals for international retail.

For instance, in November 2021, PharmaEssentia Corporation, a company based in Taiwan, announced that the U.S. Food and Drug Administration (FDA) has approved BESREMi, long-acting interferon for the treatment of adults with polycythemia vera.

“Rising awareness regarding immunostimulants therapy for chronic diseases across emerging economies, along with increasing investments in the pharmaceutical and healthcare sectors will fuel the growth in the market over the forecast period,” says an FMI analyst.

Key Takeaways:

• Based on product type, demand for vaccines is expected to increase at a 6.4% CAGR over the forecast period.
• In terms of application, the oncology segment will account for 34.7% of the total market share by 2032.
• By end user, hospital pharmacies held 34.3% of the total market share in 2021 and the trend is expected to continue over the forecast period.
• The U.S. accounted for 92.85 of the North America immunostimulants market in 2021.
• Sales in the Germany immunostimulants market are forecast to increase at a 6.4% CAGR over the assessment period.
• Demand for immunostimulants in Japan will grow at a 6% CAGR over the forecast period.

Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-15145

Competition Landscape

Leading players operating in the global immunostimulants market are investing in acquisitions and collaborations to expand their global presence. They are also investing in research and development to improve their product portfolios.

For instance: 

• In August 2021, Bayer AG acquired Vividion Therapeutics to strengthen its drug discovery platform to meet the high unmet medical needs for immune-related diseases and for oncology.
• In August 2020, Bristol Myers Squibb collaborated with Dragonfly Therapeutics and announced an exclusive global license for Dragonfly’s IL-12 investigational immunotherapy program.

Want more insights?

Future Market Insights brings a comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2032. The global immunostimulants market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the immunostimulants market segment based on by product type – (colony-stimulating factors, interferons, interleukins, and vaccines), by application- (oncology, respiratory, chronic, and autoimmune disorders, and others), by end-user (hospital pharmacies, retail pharmacies, specialty clinics, and online pharmacies), across seven major regions.

Buy Complete Report@ https://www.futuremarketinsights.com/checkout/15145

Key Market Segments Covered in Immunostimulants Industry Research

By Product:

• Colony Stimulating Factors
• Interferons
• Interleukins
• Vaccines

By Application:

• Oncology
• Respiratory
• Chronic & Autoimmune Disorders
• Others

By End-User:

• Hospital Pharmacies
• Retail Pharmacies
• Specialty Clinics
• Online Pharmacies

The human herpes simplex keratitis viruses are one of the leading cause of ophthalmic morbidity globally including cytomegalovirus retinitis in AIDS. The market of herpes simplex keratitis treatment is anticipated to grow significantly in the forecast period as the disease outbreak can cause unilateral corneal blindness worldwide. For herpes simplex keratitis treatment market, the basic understanding of how the virus behaves is helpful for manufacturers to understand the efforts that must still be concentrated on making the best use of new antiviral agents and other modes for avoiding inappropriate treatment.

Herpes Simplex Keratitis Treatment Market: Market Dynamics

The market of herpes simplex keratitis treatment is anticipated to grow significantly in the forecast period. Recurrent of herpes simplex keratitis remains the major market driver as the virus causes infectious and inflammatory eye diseases affecting all ages of the population.

The estimated prevalence of the herpes simplex keratitis disease is 15 per 10,000 population globally. The market of herpes simplex keratitis treatment is an opportunity for drug manufacturers to assess the current medicaments and their relative effectiveness of pharmacological and non-pharmacological interventions. It is estimated around 10 million persons suffered from herpes simplex keratitis eye disease worldwide, with approximately two million patients with impaired vision in their affected eye. On the grey side, the market of herpes simplex keratitis treatment is challenged by many restraints.  One of the major being, manifestation of antiviral toxicity with punctate epithelial staining in the corneal epithelium. Such effects were considered to be due to drug toxicity affecting areas of the cornea which is remote from the original lesion.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8915

Herpes Simplex Keratitis Treatment Market: Overview

The global herpes simplex keratitis treatment market is expected to witness decent growth over the forecast period. The herpes simplex keratitis treatment market is expected to grow during the forecast period due to rising awareness and increasing healthcare expenditure as well increase prevalence of herpes simplex keratitis diseases worldwide. The herpes simplex keratitis treatment market can be broadly classified into the mode of treatment delivery as orals, topical and surgical methods. Herpes simplex keratitis treatment products are distributed by hospital pharmacies, independent pharmacies, and online pharmacies.

Herpes Simplex Keratitis Treatment Market:  Region-wise Outlook

Geographically, the global herpes simplex keratitis treatment market is segmented into North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding China and Japan (APECJ), China, Japan, and the Middle East and Africa (MEA). North America is expected to be a dominant region in the global simplex keratitis treatment market, owing to the rising prevalence of Herpes Simplex Keratitis, high awareness of the general public, and high disposable income. The prevalence of a history of ocular HSV disease is about 2 to 15 per 10,000 in the U.S. population. The North America herpes simplex keratitis treatment market is followed by Western Europe market in terms of revenue share by region. Herpes simplex keratitis treatment Western Europe market revenue is significant owing to the high prevalence of epithelial keratitis with ocular herpes, good healthcare infrastructure, cost-effective diagnosis and easy availability of the medicaments. Asia-Pacific excluding China and Japan market for herpes simplex keratitis treatment is also expected to grow at a robust rate due to increase in awareness, growing research and development and increasing government support and funding. In these regions, especially government policies to help economically backward patients afford low-treatment cost is anticipated to boost the market growth for herpes simplex keratitis treatment.

Ask from Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-8915

Herpes Simplex Keratitis Treatment Market: Key Players

Some of the key players present in global herpes simplex keratitis treatment market include GlaxoSmithKline plc, Vectans Pharma, Blistex Inc, and Bausch & Lomb Incorporated, Aurobindo Pharma Ltd Dr. Reddy’s Laboratories Ltd., Cipla Ltd, Jubilant Cadista, Mylan N.V. and many more leading and local players involved in manufacturing of herpes simplex keratitis products.

The report covers exhaustive analysis on:

• Market Segments`
• Market Dynamics
• Market Size
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Value Chain

The regional analysis includes:

• North America (U.S., Canada)
• Latin America (Mexico. Brazil)
• Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
• Eastern Europe (Poland, Russia)
• Asia-Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
• Japan
• The Middle East and Africa (GCC, S. Africa, N. Africa)

For in-depth competitive analysis, Buy Now @ https://www.futuremarketinsights.com/checkout/8915

Herpes Simplex Keratitis Treatment Market: Segmentation

[250 Pages Report] As per a latest industry analysis by Future Market Insights, the global interferons market was valued at around US$ 9.1 Bn in 2021 and is anticipated to exhibit a CAGR of 3.9% over the forecast period (2022-2032).

A group of proteins produced by white blood cells, fibroblasts, and T-cells in response to viral infections, bacteria, tumor cells, and other pathogens are known as interferons. These glycoproteins, also known as cytokines, are frequently referred to as the first line of defense against pathogens.

Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15158

Interferons have proved to be a cutting-edge and successful treatment option for illnesses such as cancer, hepatitis, and multiple sclerosis. In November 2021, for instance, the FDA approved BESREMi for the treatment of adults living with polycythemia vera, which is a recent advancement in the interferons industry.

Polycythemia vera is a group of rare, chronic, and life-threatening blood cancers caused by a mutation in bone marrow stem cells, which further leads to an abundance of blood cells. When this happens, a person is at high risk of significant health problems such as blood clots, strokes, and heart attacks.

One of the other factors driving the global interferons market is rising focus of key players on the development of innovative interferon-beta medications. Key players are also focusing on expanding their presence with the help of promotions, improved distribution networks, and enhanced customer services related to their products for the betterment of the brand and products.

For instance, in March 2020, Bayer and Curadev signed a research collaboration and license agreement to develop a novel stimulator of interferon genes (STING) antagonists across indications. It is known to help activate the innate immune system in auto-inflammatory diseases. Such breakthroughs in the global market are projected to bode well for the interferons industry in the upcoming decade.

Key Takeaways: Interferons Market

• By product, interferon beta is the leading segment with a market share of around 2% in 2021.
• In terms of indication, the multiple sclerosis segment dominates the interferons market and held a share of around 0% in 2021.
• Based on end user, hospital pharmacies are expected to lead the interferons market and it generated a share of nearly 5% in 2021.
• North America is considered to be the leading region in the interferons market with a share of about 2% in 2021.

Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-15158

“Growing number of therapeutic interferon approvals and their surging commercial applications in several disease indications are expected to propel the global interferons market,” says an analyst of Future Market Insights.

Competitive Landscape: Interferons Market

Leading manufacturers such as Pfizer, Merck & Co., Zydus Cadila, and Novartis AG are focusing on collaborations and acquisitions to enhance their presence in the market and compete with their rivals during the forecast period. Below are some of the latest industry developments by key market participants:

• In March 2022, Pfizer completed the acquisition of Arena Pharmaceuticals to expand its inflammation and immunology therapeutics segment.
• In January 2022, Pfizer and Beam Therapeutics announced an exclusive collaboration to explore innovative In Vivo base editing projects for three targets in rare genetic illnesses of the liver, muscle, and central nervous system.
• In January 2022, Merck & Co. completed the acquisition of Exelead and aims to invest more than € 500 million in technical scale-up. Merck’s Life Science business segment will be able to provide comprehensive end-to-end contract development and manufacturing organization (CDMO) services across the mRNA value chain as a result of the acquisition.

More Valuable Insights on Interferons Market:

Future Market Insights brings a comprehensive research report on projected revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2032. The global interferons market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the interferons market segments based on product (interferon gamma, interferon beta, and interferon alpha), indication (multiple sclerosis, polycythemia vera, hepatitis C, melanoma, chronic granulomatous disease (CGD), and other indications), and end user (hospital pharmacies, retail pharmacies, specialty clinics, and online pharmacies) across seven major regions.

For in-depth insights, Download a PDF Brochure@ https://www.futuremarketinsights.com/reports/brochure/rep-gb-15158

Interferons Market Outlook by Category

By Product:

• Interferon Gamma
• Interferon Beta
• Interferon Alpha

By Indication:

• Multiple Sclerosis
• Polycythemia Vera
• Hepatitis C
• Melanoma
• Chronic Granulomatous Disease (CGD)
• Other Indications

By End User:

• Hospital Pharmacies
• Retail Pharmacies
• Specialty Clinics
• Online Pharmacies

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Future Market Insights (FMI), in its report, projects the global oral solid dosage pharmaceutical formulation market to register 6.5% CAGR during the forecast period 2017 to 2027. In terms of revenue, the market will reach nearly US$ 500,000 Mn in 2017; by 2027 is further estimated to surpass US$ 900,000 Mn.

Instead of increasing pipeline productivity for biologics and patent cliff challenges, oral solid dosage forms hold substantial opportunity in extending product lifecycle and leveraging growth potential. Manufacturers are employing various life cycle management patent strategies which include obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations.

North America to Remain Largest Market for Oral Solid Dosage Pharmaceutical Formulation

North America will remain the largest market for oral solid dosage pharmaceutical formulation, followed by Asia Pacific Excluding Japan (APEJ) and Western Europe. Revenue from the market in North America is expected to surpass US$ 300,000 Mn by 2027-end. In addition, APEJ is projected to reach revenue worth US$ 294,750.4 Mn in the market by 2027. Latin America is expected to be the fastest growth region in the market, expanding at 9.2% CAGR through 2027. In contrast, Japan will witness a sluggish growth in the market.

Request for Report Sample @

http://www.futuremarketinsights.com/reports/sample/rep-gb-2782

By dosage form, tablets will continue to remain preferred in the market, with sales estimated to surpass US$ 500,000 Mn by 2027-end. Sales of tablets are anticipated to exhibit the highest CAGR in the market, followed by capsules. Capsules are expected to be the second most lucrative dosage form in the market, expanding at 6.1% CAGR through 2027.

Immediate Release to Remain Dominant in the Market during 2017-2027

Based on release mechanism, immediate release will remain dominant in the market, expanding at 6.4% CAGR through 2027. Immediate release is expected to generate revenue over US$ 400,000 Mn by 2027-end. Controlled release under extended release segment, is expected to register 7.4% CAGR through 2027.

Retail pharmacy is expected to be the largest end-user of oral solid dosage pharmaceutical formulation market by 2027-end. Retail pharmacy is expected to exhibit highest CAGR in the market through 2027. In contrast, Hospital pharmacy is expected to exhibit lowest CAGR, even though it stands as second largest end-user in the market during the forecast period.

Speak to our Research Expert @ 

https://www.futuremarketinsights.com/ask-question/rep-gb-2782

Increasing Presence of MNCs to Drive Market Growth in Latin America

Latin America is emerging as a manufacturing hub for oral solid dosage forms on the back of availability of low-cost resources. Multinational companies are focusing on expanding their presence in this region. These factors are expected to propel market growth in Latin America. Oral solid dosage forms are cost-effective and comparatively easy to manufacture than other dosage forms. They are most commonly used pharmaceuticals for treating various disease conditions in North America, which in turn is driving growth of the market in this region.

Growing effluent consumers in APEJ countries such as China, India and Korea are boosting growth of the oral solid dosage pharmaceutical formulation market in this region. Consumers here are adopting wealthy-life-fast-paced western lifestyle, leading them to suffer western lifestyle-related diseases including diabetes, cancer, and obesity. This compels them in seeking innovative drug treatments, which in turn is expected to fuel market growth in APEJ. However factors such as decreasing productivity of Asian manufacturers and containment issues, and low R&D expenditure coupled with challenges incurred in USFDA compliance are expected to impede growth of the market in APEJ.

Key players identified in FMI’s report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceuticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc.

Report Customization available @ 

https://www.futuremarketinsights.com/customization-available/rep-gb-2782

Why Future Market Insights?

• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of the Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favour the market growth in various segments based on Source, Application, Sales Channel and End-Use over the next 10-years.

Contact:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

Website: https://www.futuremarketinsights.com

LinkedIn| Twitter| Blogs

As per a recent study by Future Market Insights (FMI), the global ambulatory surgical centers market totaled US$ 85.4 Bn in 2020. With sales growing at a 3.9% CAGR, the market valuation is poised to reach US$ 130.6 Bn by 2031.

Increasing number of clinical procedures such as lithotripsy, coronary angiography, hemodialysis, radiotherapy (for cancer), and chemotherapy is driving demand for ambulatory surgical centers. Earlier, all clinical condition were treated in the hospital, be it a simple suturing procedure or a deep invasive procedure. These minimal invasive procedures led the count of inpatient admissions to increase, resulting in disorganization in the hospital environment.

When a common outpatient procedure is performed in the ambulatory surgical center it saves up to 59% of the total spending, according to the Ambulatory Surgery Center Association.

These factors are driving investments in hospitals for the establishment of ambulatory surgical centers. This is expected to create lucrative opportunities for platers operating in the market, especially in developing regions.

“Growing demand for mobile healthcare services, coupled with favorable government policies encouraging the establishment of these centers in rural areas is expected to drive the market in the forthcoming years,” says an FMI analyst.

Request for Report Sample @

https://www.futuremarketinsights.com/reports/sample/rep-gb-5071

Key Takeaways:

• By centers type, the multispecialty centers segment is projected to account for 66.2%of the total market share in 2021, expanding at 4.3% CAGR during the forecast period.
• Based on modality, the hospital-based segment is forecast to hold 60.2% of the market share in 2021.
• Sales in the surgical services segment are anticipated to account for 68.1% of the total market share in 2021.
• Demand in the gastroenterology segment is expected to command 30% of the total market share over the assessment period.
• The U.S. forecast to account for 88.3% of the North America market share over the assessment period.
• Sales in Germany are forecast to command 31.6% of the Europe market share in 2031.
• China will emerge as a lucrative market, holding 45% of the East Asia market share over the forecast period.

Who is winning?

Key market players covered by FMI include AmSurg Corp, Tenet Healthcare, HCA Holdings, Inc., Surgical Care Affiliates, Inc., Surgery Partners, and Ambulatory Surgical Centers of America.

Leading players operating in the global ambulatory surgical centers market are focusing on new service offering, collaborations, and partnerships to improve their product portfolios, and to strengthen their global presence. For instance:

• In June 2021, Tenet Healthcare Corporation (NYSE: THC), and its subsidiary United Surgical Partners International (USPI) acquired SurgCenter Development (SCD) which will provide service for musculoskeletal facilities which is said to be a high growth Service line.
• In September 2019, Tenet Healthcare Corporation and NTT DATA Services signed a new agreement that focuses on developing more efficient and well-organized infrastructure for the hospitals, and ambulatory centers. This agreement fits into a transformation of digital strategies and prioritizing straight into technological innovations. Furthermore, these innovations will help deliver quality services

Speak to our Research Expert @ 

https://www.futuremarketinsights.com/ask-question/rep-gb-5071

Want more insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global ambulatory surgical centers market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

The study provides compelling insights into the Ambulatory Surgical Centers market. The ambulatory surgical centers market is segmented into five parts based on centers (single specialty centers and multispecialty centers), modality (hospital-based ambulatory surgical center, and freestanding ambulatory surgical center), services (diagnostic services and surgical services) and specialty area (gastroenterology, ophthalmology, orthopedics, pain/neurology, urology, dermatology) across seven major regions.

Report Customization available @ 

https://www.futuremarketinsights.com/customization-available/rep-gb-5071

Why Future Market Insights?

• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of the Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favour the market growth in various segments based on Source, Application, Sales Channel and End-Use over the next 10-years.

Contact:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

Website: https://www.futuremarketinsights.com

LinkedIn| Twitter| Blogs